Last reviewed · How we verify
Prevention of pulmonary embolism — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Xarelto | rivaroxaban | Johnson & Johnson | Direct Factor Xa Inhibitor | Factor Xa (FXa) | 2011-01-01 | |
| Xarelto | Xarelto | University Hospital, Montpellier | Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Johnson & Johnson · 1 drug in Prevention of pulmonary embolism
- University Hospital, Montpellier · 1 drug in Prevention of pulmonary embolism
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of pulmonary embolism:
- Prevention of pulmonary embolism treatment updates — RSS
- Prevention of pulmonary embolism treatment updates — Atom
- Prevention of pulmonary embolism treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of pulmonary embolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-pulmonary-embolism. Accessed 2026-06-10.
Related
- Prevention of pulmonary embolism full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing